Pfizer, Astellas prostate cancer drug succeeds key trial
Pfizer Inc and Japan`s Astellas Pharma Inc said on Thursday their prostate cancer drug met the main goal of a trial testing it for a more common form of the disease.
The drug, Xtandi, is already approved to treat metastatic castration-resistant prostate cancer (CRPC) - where the cancer has spread to other parts of the body - and raked in U.S. sales of $141 million in the second quarter for Pfizer.
An approval to treat non-metastatic CRPC would significantly boost sales of Xtandi, which Pfizer got access to when it bought Medivation for $14 billion last year. Astellas owns the rights to sell Xtandi outside the United States.
Pfizer said on Thursday that Xtandi, in combination with an anti-hormone therapy, was statistically significant in improving survival rate in men with non-metastatic CRPC without their cancer spreading, when compared with the standalone anti-hormone therapy.
Patients with CRPC experience cancer progression despite androgen deprivation therapy, a treatment that blocks the production of the hormone.
Pfizer is pinning its growth on the success and approvals of 15 drugs over the next five years, a list that includes Xtandi and breast cancer drug Ibrance.
Earlier this month, the U.S. Food and Drug Administration approved Pfizer`s Mylotarg for certain patients with acute myeloid leukemia, re-clearing a drug that had been pulled off the market in 2010.
Prostate cancer a big market for drugmakers. More than 161,000 men are estimated to be diagnosed with prostate cancer in 2017 in the United States, according to the American Cancer Society.
Pfizer`s shares rose 1.4 percent to $35.55 in light premarket trading.
(This article has not been edited by Zeebiz editorial team and is auto-generated from an agency feed.)
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.